Noevir Holdings Co Ltd

Chart & Performance

D1W1MN

P/E

19.54

P/S

2.44

EPS

233.34

Div Yield, %

4.78%

Shrs. gr., 5y

—

Rev. gr., 5y

1.50%

Revenues

63.82b

+2.03%

Net income

7.97b

+3.87%

CFO

9.12b

+19.66%

Dividend

Sep 27, 2024220 JPY/sh

Profile

Noevir Holdings Co., Ltd. develops, produces, and sells cosmetics, pharmaceuticals, and health food products in Japan, China, Taiwan, South Korea, Hong Kong, Singapore, Thailand, the United States, Canada, and Russia. The company's Cosmetics segment develops, produces, and sells skincare products under various brands, including Noevir and Nameraka Honpo; and NOV hypoallergenic cosmetics, as well as provides contract manufacturing services for cosmetics and quasi drugs. Its Pharmaceutical & Health Food segment produces and sells Nanten Nodo Ame cough drops; functional drinks, such as the Min Min Da Ha; and over-the-counter pharmaceuticals comprising cold remedies, eye drops, and digestive aids, as well as nutritional supplements, and other products. The company's Other segment sells and leases apparels and aircrafts. The company also produces and sells toiletries; purchases and sells makeup products and vessels; and provides market research services. In addition, it provides air transportation, charter flights, ground handling, and hanger rental services; and aircraft flight training, as well as undertakes aviation-related operations. The company sells its products through drug stores, specialty goods and general merchandise stores, supermarkets, online stores, and convenience stores, as well as approximately 2,000 Noevir beauty studios and own retail stores. Noevir Holdings Co., Ltd. was founded in 1964 and is headquartered in Tokyo, Japan.

URL

https://www.noevirholdings.co.jp/

IPO date

Mar 22, 2011

Employees

1,398

Domiciled in

Incorporated in

Valuation

Order:

Title JPY in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title JPY in thousands, except ratios and share amounts	2024‑09	2023‑09	2022‑09	2021‑09	2020‑09	2019‑09	2018‑09	2017‑09	2016‑09	2015‑09
Income
Revenues	63,823,000 2.03%	62,552,000 2.30%	61,143,000 19.25%
Cost of revenue	31,583,000	52,557,000	31,171,000
Unusual Expense (Income)
NOPBT	32,240,000	9,995,000	29,972,000
NOPBT Margin	50.51%	15.98%	49.02%
Operating Taxes	3,530,000	3,484,000	3,506,000
Tax Rate	10.95%	34.86%	11.70%
NOPAT	28,710,000	6,511,000	26,466,000
Net income	7,970,000 3.87%	7,673,000 1.11%	7,589,000 18.89%
Dividends	(7,522,000)	(7,341,000)	(7,166,000)
Dividend yield	4.26%	4.06%	3.69%
Proceeds from repurchase of equity
BB yield
Debt
Debt current	86,000	87,000	93,000
Long-term debt	1,570,000	1,741,000	1,917,000
Deferred revenue
Other long-term liabilities	11,843,000	12,247,000	13,522,000
Net debt	(27,567,000)	(29,666,000)	(29,869,000)
Cash flow
Cash from operating activities	9,123,000	7,624,000	5,845,000
CAPEX	(626,000)	(736,000)	(613,000)
Cash from investing activities	1,525,000	(3,544,000)	(255,000)
Cash from financing activities	(7,712,000)	(7,493,000)	(7,380,000)
FCF	29,607,000	4,253,000	28,053,000
Balance
Cash	29,223,000	28,883,000	29,747,000
Long term investments		2,611,000	2,132,000
Excess cash	26,031,850	28,366,400	28,821,850
Stockholders' equity	51,515,000	53,206,000	52,385,000
Invested Capital	40,544,150	37,999,600	37,003,150
ROIC	73.11%	17.36%	70.14%
ROCE	47.95%	14.96%	45.32%
EV
Common stock shares outstanding	34,156	34,156	34,156
Price	5,170.00 -2.27%	5,290.00 -6.87%	5,680.00 6.57%
Market cap	176,588,154 -2.27%	180,687,107 -6.87%	194,008,227 6.57%
EV	149,449,154	151,436,107	164,467,227
EBITDA	33,249,000	11,215,000	31,423,000
EV/EBITDA	4.49	13.50	5.23
Interest			10,000
Interest/NOPBT			0.03%